Alexandre Zanghellini co-founded Arzeda and leads the team as CEO and Vice President, Research. Alexandre is an internationally recognized protein design expert and was the early developer of Arzeda’s protein design software Archytas™ for enzyme design, as well as Arzeda’s metabolic pathway design software Scylax™. Before Arzeda, Alexandre led bioinformatics at Cellectis (NASDAQ: CLLS), a publicly traded protein engineering and gene editing company.​Alexandre strongly believes the convergence of big compute, machine learning, DNA synthesis and lab automation represent an inflexion point in human history, and that the rationale design of new proteins will play a key role in solving some of humanity’s biggest societal challenges – from improving human well-being to combating climate change. Alexandre holds a Ph.D. in Biochemistry from University of Washington, a M.S. in Computer Science (Artificial Intelligence) and B.S. in Applied Mathematics, both from University of Paris, and a M.Eng. from ENSTA/ParisTech.